| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5292740 | ACTELION | Sulfonamides |
Nov, 2015
(8 years ago) | |
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(2 years from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(3 years from now) | |
Tracleer is owned by Actelion.
Tracleer contains Bosentan.
Tracleer has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Tracleer are:
- US5292740
Tracleer was authorised for market use on 20 November, 2001.
Tracleer is available in tablet, for suspension;oral, tablet;oral dosage forms.
The generics of Tracleer are possible to be released after 28 December, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Sep 05, 2024 |
| New Patient Population(NPP) | Sep 05, 2020 |
| New Indication(I-607) | Aug 07, 2012 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 20 November, 2001
Treatment: NA
Dosage: TABLET;ORAL; TABLET, FOR SUSPENSION;ORAL
How can I launch a generic of TRACLEER before it's drug patent expiration?
More Information on Dosage
TRACLEER family patents
